it’s definitely not as simple as that… think of it from the inventors point of view, it’s their life’s work. And they have a lot more important work that needs funding. It’s a competitive process, where many suitors come and bid for the rights to their life’s work.
So if they have something amazing on their hands, they will want to license it out to a team they believe will have a good chance of bringing it to market.
So CHM’s management team had everything to do with getting CORE-NK, and even if ALA tried… I don’t think they would have had a chance against other parties competing for this platform.
PH probably did the best he can for SUD, with what SUD had to offer the inventor… which really shows what a strong management team, head hunted from the largest and most successful pharma companies in the cell therapy space can achieve.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)